ROS1 fusion-positive non-small cell lung cancer—repotrectinib as a new treatment option
Open Access
- 1 June 2025
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (6) , 3272-3276
Abstract
ROS1 fusion-positive non-small cell lung cancer—repotrectinib as a new treatment optionKeywords
This publication has 22 references indexed in Scilit:
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery, 2017
- ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityOncotarget, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007
- Characterization of an activated human ros gene.Molecular and Cellular Biology, 1986
- Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.Molecular and Cellular Biology, 1986